Abiomed - ABMD Stock Forecast, Price & News

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Abiomed Stock Down 1.3 %

ABMD opened at $291.12 on Wednesday. Abiomed has a 12 month low of $219.85 and a 12 month high of $379.30. The company has a fifty day simple moving average of $266.21 and a 200 day simple moving average of $282.93. The stock has a market cap of $13.28 billion, a P/E ratio of 61.42 and a beta of 1.35.

Abiomed (NASDAQ:ABMD - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The medical equipment provider reported $1.25 EPS for the quarter, beating analysts' consensus estimates of $1.06 by $0.19. Abiomed had a net margin of 20.60% and a return on equity of 14.33%. The business had revenue of $277.15 million during the quarter, compared to analysts' expectations of $276.46 million. During the same quarter in the prior year, the company earned $1.10 EPS. The firm's quarterly revenue was up 9.7% on a year-over-year basis. On average, equities research analysts expect that Abiomed will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ABMD. Morgan Stanley dropped their price objective on shares of Abiomed from $275.00 to $235.00 and set an "underweight" rating for the company in a research report on Friday, July 15th. StockNews.com cut shares of Abiomed from a "buy" rating to a "hold" rating in a research report on Friday, July 1st. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of Abiomed from $410.00 to $355.00 in a research report on Thursday, July 21st.

Insider Activity at Abiomed

In related news, CFO Todd A. Trapp sold 1,000 shares of the company's stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $300.00, for a total value of $300,000.00. Following the completion of the sale, the chief financial officer now owns 16,927 shares in the company, valued at approximately $5,078,100. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.50% of the stock is owned by corporate insiders.